QurAlis is breaking through the barriers of science in our quest to bring much-needed precision therapies to patients.

QurAlis is currently advancing a pipeline with therapeutic candidates that target specific components of ALS pathology and defined ALS patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.

We are focused on patients who have loss of STATHMIN-2 (STMN2), and patients who have a loss of Kv7, as well as patients with TDP-43 gain-of-function toxicity and autophagy impairment. The QurAlis team is leveraging insights, platforms, and successes in ALS to collaborate and expand our pipeline to other neurodegenerative diseases, such as FTD.

Our lead therapeutic product candidates are:

  • QRL-201: a first-in-class molecule for the treatment of ALS that aims to restore STMN2 expression in ALS patients.
  • QRL-101: a first-in-class Kv7 opener for the treatment of ALS that aims to reduce hyperexcitability-induced neurodegeneration.


(STMN2) is a well-known and important member of a family of proteins that play critical roles in neural repair, and axon and microtubule stability. The expression of this protein is significantly decreased in ALS patients, contributing to motor neuron loss and cytoskeletal weakness. In animal models, STMN2 deletion was found to cause axonal degeneration, which is the leading functional deficit that drives paralysis in ALS patients.


is a voltage-gated potassium channel whose role is crucial for the regulation of neuronal excitability and membrane potential. Kv7.2/7.3 deactivation leads to abnormal electrical activity in the brain. The activation of this channel shows the potential to decrease spinal and cortical/motor neuron excitability and to positively affect CMAP (compound muscle action potential). This suggests that this may be an effective therapeutic approach for ALS patients suffering from hyperexcitability-induced motor neuron degeneration.


is an essential regulator of neurotransmitter release at synapses. In ALS and FTD, the loss of TDP-43 causes the mis-splicing of certain pre-mRNA transcripts resulting in expression of a cryptic exon-containing transcript that interferes with appropriate protein generation. UNC13A is a pre-mRNA that is mis-spliced due to loss of TDP-43 in disease. Up to 63 percent of ALS patients and up to one-third of FTD patients carry a single nucleotide polymorphism in the UNC13A gene or show TDP-43 pathology which greatly exacerbates UNC13A mis-splicing leading to loss of function of the UNC13A protein.


QR43™: Proprietary & Investigative TDP-43 Platform

Investigative platform dedicated to discovering and developing precision therapies for TDP-43-related diseases

Learn More

FlexASO™: Proprietary Anti-Sense Oligonucleotide Splice Modulator Platform

Bespoke platform key to tackling the spectrum of diseases that define ALS and other diseases

Learn More

Latest Press Releases